S 1095

Summary

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Bill status

Status

Reported

Sponsor

Sen. Amy Klobuchar [D-MN]

Cosponsors

6

Policy area

Health

Introduced

2025-03-24

Latest action

2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Committee referrals

• Judiciary Committee: Senate · Reported By · 2025-04-10
• Judiciary Committee: Senate · Markup By · 2025-04-03
• Judiciary Committee: Senate · Referred To · 2025-03-24

Recent actions

• 2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
• 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
• 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
• 2025-04-03: Committee on the Judiciary. Ordered to be reported without amendment favorably.
• 2025-03-24: Read twice and referred to the Committee on the Judiciary.